SCHEMBL21629598

SCHEMBL21629598

CC(Oc1cc(F)c2c(-c3ccccc3)cc(=O)oc2c1)C(=O)N(C)C

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 8/20 0.54
▸ HPGD P15428 3/20 0.54
▸ MAPK1 P28482 2/20 0.47
▸ HSD17B10 Q99714 1/20 0.47
▸ KDM4E B2RXH2 2/20 0.45
▸ RECQL P46063 2/20 0.45
▸ ALOX15 P16050 1/20 0.44
▸ TSHR P16473 1/20 0.44
▸ POLB P06746 1/20 0.43
▸ MAP1LC3B Q9GZQ8 1/20 0.43
▸ MEN1 O00255 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ KLK7 P49862 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ MAPT P10636 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21630173 0.89 ALDH1A1 (0.68) ALDH1A1HPGDMAPK1KDM4ERECQL
SCHEMBL21629591 0.84 ALDH1A1 (0.55) ALDH1A1HPGDMAPK1HSD17B10KDM4E
SCHEMBL21629532 0.83 ALDH1A1 (0.79) ALDH1A1HPGDKDM4ERECQLKMT2A
SCHEMBL21629535 0.83 ALDH1A1 (0.79) ALDH1A1HPGDKDM4ERECQLKMT2A
SCHEMBL30231646 0.82 ALDH1A1 (0.46) ALDH1A1HPGDMAPK1HSD17B10KDM4E
SCHEMBL30228241 0.74 ALDH1A1 (0.57) ALDH1A1HPGDMAPK1HSD17B10KDM4E
SCHEMBL30360940 0.74 ALDH1A1 (0.58) ALDH1A1HPGDHSD17B10KDM4ERECQL
SCHEMBL20839429 0.74 ALDH1A1 (0.58) ALDH1A1HPGDHSD17B10KDM4ERECQL
SCHEMBL20839406 0.72 ALDH1A1 (0.59) ALDH1A1HPGDHSD17B10KDM4ERECQL
SCHEMBL20839115 0.72 ALDH1A1 (0.59) ALDH1A1HPGDHSD17B10KDM4ERECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240252454-A1 COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION LEAD DISCOVERY CENTER GMBH (DE) 2024-08-01 — — US claimed
US-10703735-B2 4-phenyl-coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer LEAD DISCOVERY CENTER GMBH (DE) 2020-07-07 — — US claimed
US-20200031794-A1 4-PHENYL-COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER LEAD DISCOVERY CENTER GMBH (DE) 2020-01-30 — — US claimed
US-20240252454-A1 COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION LEAD DISCOVERY CENTER GMBH (DE) 2024-08-01 — — US disclosed
EP-4333822-A1 COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION Lead Discovery Center GmbH (DE) 2024-03-13 — — EP disclosed
WO-2022233782-A1 COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION LEAD DISCOVERY CENTER GMBH (DE) 2022-11-10 — — WO disclosed
US-10703735-B2 4-phenyl-coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer LEAD DISCOVERY CENTER GMBH (DE) 2020-07-07 — — US disclosed
US-10703735-B2 4-phenyl-coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer LEAD DISCOVERY CENTER GMBH (DE) 2020-07-07 — — US disclosed
US-20200031794-A1 4-PHENYL-COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER LEAD DISCOVERY CENTER GMBH (DE) 2020-01-30 — — US disclosed
US-20200031794-A1 4-PHENYL-COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER LEAD DISCOVERY CENTER GMBH (DE) 2020-01-30 — — US disclosed
EP-3598972-A1 4-PHENYL-COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER Lead Discovery Center GmbH (DE) 2020-01-29 — — EP disclosed
EP-3598972-A1 4-PHENYL-COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER Lead Discovery Center GmbH (DE) 2020-01-29 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240252454-A1 COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION TFAM, POLRMT, TUFM ALDH1A1 3415/4885HPGD 1853/4885MAPK1 3533/4885
US-20200031794-A1 4-PHENYL-COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER POLRMT, COX4I1, UQCRC2 ALDH1A1 1344/4885HPGD 1377/4885MAPK1 3198/4885
US-10703735-B2 4-phenyl-coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer POLRMT, COX4I1, UQCRC2 ALDH1A1 1344/4885HPGD 1377/4885MAPK1 3198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback